Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery

Phase 2

Active, not recruiting

Conditions: Gastric Neuroendocrine Carcinoma
Pancreatic Neuroendocrine Carcinoma
Intestinal Neuroendocrine Carcinoma

Interventions: Drug: Carboplatin
Drug: Capecitabine
Other: Laboratory Biomarker Analysis
Drug: Cisplatin
Drug: Temozolomide
Drug: Etoposide

First Posted Date: 2015-11-03

Last Posted Date: 2024-12-10

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 67

Registration Number: NCT02595424

Locations: 🇺🇸
Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States
🇺🇸
Grant Medical Center, Columbus, Ohio, United States
🇺🇸
Doctors Hospital, Columbus, Ohio, United States

and more 668 locations

Neoadjuvant Chemotherapy and Radical Surgery in Stage IIB Cervical Cancer

Phase 3

Conditions: Cervical Carcinoma Stage IIB

Interventions: Radiation: Concurrent chemoirradiation
Drug: Paclitaxel
Procedure: Radical Surgery
Drug: Cisplatin

First Posted Date: 2015-11-03

Last Posted Date: 2017-02-03

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 220

Registration Number: NCT02595554

Locations: 🇨🇳
Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Pembrolizumab in Combination With CRT for LA-SCCHN

Phase 1

Active, not recruiting

Conditions: Oropharynx Cancer
Hypopharynx Cancer
Larynx Cancer
Laryngeal Cancer
Head and Neck Cancer
Squamous Cell Carcinoma
Oral Cavity Cancer

Interventions: Drug: pembrolizumab (MK-3475)
Drug: Cisplatin
Radiation: Radiation

First Posted Date: 2015-10-26

Last Posted Date: 2024-07-19

Lead Sponsor: Sanford Health

Target Recruit Count: 59

Registration Number: NCT02586207

Locations: 🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸
Sanford-Bismarck Medical Center, Bismarck, North Dakota, United States
🇺🇸
Sanford-Roger Maris Cancer Center, Fargo, North Dakota, United States

and more 1 locations

Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC

Phase 1

Completed

Conditions: Carcinoma, Squamous Cell of Head and Neck

Interventions: Drug: AZD1775
Drug: Cisplatin
Radiation: Intensity Modulated Radiotherapy Treatments

First Posted Date: 2015-10-26

Last Posted Date: 2021-06-29

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 12

Registration Number: NCT02585973

Locations: 🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Phase 3

Conditions: Germ Cell Tumor

Interventions: Drug: Etoposide
Drug: Cisplatin
Drug: Pegylated G-CSF (Pegfilgrastim)
Drug: Filgrastim

First Posted Date: 2015-10-21

Last Posted Date: 2021-11-29

Lead Sponsor: University of Sydney

Target Recruit Count: 500

Registration Number: NCT02582697

Locations: 🇦🇺
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇦🇺
Prince of Wales Hospital, Sydney, New South Wales, Australia
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia

and more 25 locations

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)

Phase 3

Completed

Conditions: Non-Small-Cell Lung Carcinoma

Interventions: Biological: Pembrolizumab 200 mg
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed
Dietary Supplement: Folic acid 350-1000 μg
Dietary Supplement: Vitamin B12 1000 μg
Drug: Dexamethasone 4 mg
Drug: Saline solution

First Posted Date: 2015-10-19

Last Posted Date: 2024-07-09

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 616

Registration Number: NCT02578680

Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients

Phase 3

Conditions: Malignant Hydrothorax
Non Small Cell Lung Cancer

Interventions: Drug: Gemcitabine
Drug: Vinorelbine
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Oncorine
Drug: Cisplatin
Drug: Endostar

First Posted Date: 2015-10-19

Last Posted Date: 2016-10-21

Lead Sponsor: Xinqiao Hospital of Chongqing

Target Recruit Count: 134

Registration Number: NCT02579564

Avelumab in First-line NSCLC (JAVELIN Lung 100)

Phase 3

Completed

Conditions: First Line Non-Small Cell Lung Cancer

Interventions: Drug: Avelumab
Drug: Cisplatin
Drug: Pemetrexed
Drug: Paclitaxel
Drug: Avelumab Weekly
Drug: Gemcitabine
Drug: Carboplatin

First Posted Date: 2015-10-15

Last Posted Date: 2024-03-20

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 1214

Registration Number: NCT02576574

Locations: 🇧🇪
A.Z. Klina, Brasschaat, Belgium
🇦🇺
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇺🇸
Arizona Center for Cancer Care, Surprise, Arizona, United States

and more 344 locations

Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)

Phase 2

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck
Carcinoma, Squamous Cell of the Head and Neck
Cancer of Head and Neck
Cancer of the Head and Neck
Head and Neck Cancer
Neoplasms, Head and Neck

Interventions: Drug: nab-Paclitaxel
Biological: Cetuximab
Drug: Cisplatin
Radiation: Intensity-Modulated Radiation Therapy

First Posted Date: 2015-10-09

Last Posted Date: 2024-12-27

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 96

Registration Number: NCT02573493

Locations: 🇺🇸
Sanford Cancer Center, Sioux Falls, South Dakota, United States
🇺🇸
The University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer

Early Phase 1

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Carboplatin
Drug: Cisplatin
Drug: Docetaxel
Drug: Paclitaxel
Radiation: stereotactic radiosurgery

First Posted Date: 2015-10-05

Last Posted Date: 2017-01-31

Lead Sponsor: The Cooper Health System

Target Recruit Count: 22

Registration Number: NCT02568033

Locations: 🇺🇸
MD Anderson Cancer Center at Cooper, Camden, New Jersey, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy